PMID- 18767953
OWN - NLM
STAT- MEDLINE
DCOM- 20081023
LR  - 20080904
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 7
IP  - 7
DP  - 2008 Sep
TI  - Dendritic cell-based cancer vaccination: quo vadis?
PG  - 1041-53
LID - 10.1586/14760584.7.7.1041 [doi]
AB  - Dendritic cells (DCs) play a central role in the initiation and regulation of 
      primary immune responses. DCs loaded with tumor-associated antigens induce 
      anti-tumoral cytotoxic T cells in vitro and in vivo. However, clinical trials 
      using ex vivo-generated DCs have failed to demonstrate clinical efficacy. This 
      review summarizes recent advances in concepts and techniques that are providing 
      new impulses to DC-based cancer vaccination. Improvements in protocols for ex 
      vivo-generation of DCs, innovations in immunomonitoring, strategies to overcome 
      tumor-induced immunosuppression and insights into the mutual beneficial effects 
      of vaccines and chemotherapy are all considered. Furthermore, we highlight novel 
      developments in cell-free vaccines targeting DCs in vivo.
FAU - Dauer, M
AU  - Dauer M
AD  - Department of Gastroenterology, Hepatology & Endocrinology (Medizinische Klinik 
      II), Saarland University Hospital, Kirrberger Str., 66421 Homburg/Saar, Germany. 
      marc.dauer@uniklinikum-saarland.de
FAU - Schnurr, M
AU  - Schnurr M
FAU - Eigler, A
AU  - Eigler A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Neoplasms/immunology/*therapy
MH  - Vaccination/*methods
RF  - 121
EDAT- 2008/09/05 09:00
MHDA- 2008/10/24 09:00
CRDT- 2008/09/05 09:00
PHST- 2008/09/05 09:00 [pubmed]
PHST- 2008/10/24 09:00 [medline]
PHST- 2008/09/05 09:00 [entrez]
AID - 10.1586/14760584.7.7.1041 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2008 Sep;7(7):1041-53. doi: 10.1586/14760584.7.7.1041.